These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29535389)

  • 1. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Sodium Glucose Cotransporter-2 Inhibitors on Hemoglobin A1c Variability and Acute Kidney Injury: A Causal Mediation Analysis.
    Wang T; Ji D; Stürmer T; Ismail S; Dong S; Shen P; Lin H; Shi L; Guan X; Xu Y
    Pharmacoepidemiol Drug Saf; 2024 Aug; 33(8):e5876. PubMed ID: 39090775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
    Yang W; Cai X; Gao X; Chen Y; Chen L; Ji L
    J Diabetes Investig; 2018 Jul; 9(4):813-821. PubMed ID: 29047219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
    Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preconception SGLT2 or DPP4 inhibitor use and adverse pregnancy outcomes.
    Ray JG; Harel Z; Gilbert RE; Wald R; Berger H; Park AL
    Diabetes Res Clin Pract; 2023 Nov; 205():110946. PubMed ID: 37813164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.
    Wu T; Wong CKH; Lui DTW; Wong SKH; Lam CLK; Chung MSH; McAllister DA; Welbourn R; Dixon JB
    BJS Open; 2023 Jul; 7(4):. PubMed ID: 37542473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
    Shikamura M; Takayama A; Takeuchi M; Kawakami K
    Diabetes Obes Metab; 2024 Aug; 26(8):3099-3109. PubMed ID: 38708591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
    J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.
    Cho YK; Kim YJ; Kang YM; Lee SE; Park JY; Lee WJ; Jung CH
    J Diabetes Investig; 2018 Jul; 9(4):882-892. PubMed ID: 29215196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
    Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
    Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
    Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors.
    Suzuki Y; Kaneko H; Okada A; Komuro J; Fujiu K; Takeda N; Morita H; Ako J; Nishiyama A; Yano Y; Ieda M; Node K; Yasunaga H; Komuro I
    Hypertens Res; 2024 Jul; 47(7):1789-1796. PubMed ID: 38600275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Wang M; Li M; Wang L; Wang F; Cao X; Li S; Zheng Z
    Can J Diabetes; 2024 Aug; 48(6):364-372.e1. PubMed ID: 38636589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Drake T; Landsteiner A; Langsetmo L; MacDonald R; Anthony M; Kalinowski C; Ullman K; Billington CJ; Kaka A; Sultan S; Wilt TJ
    Ann Intern Med; 2024 May; 177(5):618-632. PubMed ID: 38639549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.